Blog
RSS FeedPosted by Michael Wonder on 06 Sep 2021
Health economic assessment of Sarclisa in multiple myeloma
6 September 2021 - TLV has produced a health economic assessment for the regions for the drug Sarclisa (isatuximab) in combination ...
Posted by Michael Wonder on 19 Aug 2021
EndoPredict for breast cancer - the company chose not to participate with data
19 August 2021 - In November 2020, Myriad Genetics chose to refrain from participating in a health economic assessment of EndoPredict. ...
Posted by Michael Wonder on 11 Aug 2021
Withdrawals from the pharmaceutical benefits on 1 September 2021
10 August 2021 - Faslodex is among the medicines being withdrawn from the drug benefits on 1 September 2021. ...
Posted by Michael Wonder on 15 Jul 2021
Health economic assessment of Oncotype DX in breast cancer
12 July 2021 - At the request of the regions' medical technology product council, the MTP council, TLV has carried out ...
Posted by Michael Wonder on 01 Jul 2021
2021's first forecast of savings from side agreements
28 June 2021 - In a new report to the government, TLV forecasts that the pharmaceutical companies will pay approximately ...
Posted by Michael Wonder on 22 Jun 2021
Update of handbook for companies applying for a subsidy
18 June 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has updated parts of the handbook for companies ...
Posted by Michael Wonder on 16 Jun 2021
TLV receives a new assignment for precision medicine and advanced therapy drugs
15 June 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, is commissioned by the government to continue the ...
Posted by Michael Wonder on 16 Jun 2021
Sweden's cost of medicines is increasing
15 June 2021 - Sweden's costs for pharmaceuticals have risen by approximately SEK 2 billion between 2019 and 2020. ...
Posted by Michael Wonder on 17 May 2021
The national health data registers are the way forward
17 May 2021 - The key to developing follow-up of medicines and medical technology products is the national health data registers, ...
Posted by Michael Wonder on 07 May 2021
The National Audit Office's review can contribute to strengthening TLV's work
7 May 2021 - On 6 May, the National Audit Office published its report on the Government's and TLV's work ...
Posted by Michael Wonder on 04 May 2021
Uncertain effect and high prices of precision medicine are challenging
3 May 2021 - In a report to the government, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, describes the most ...
Posted by Michael Wonder on 03 May 2021
TLV reconsiders subsidy for eleven TNF alfa inhibitors included in the high-cost protection
30 April 2021 - Today, eleven subcutaneous TNF-alpha inhibitors are included in the high-cost protection. ...
Posted by Michael Wonder on 21 Apr 2021
Additional analysis of Luxturna in the treatment of visual impairment caused by hereditary eye disease
21 April 2021 - TLV has made a supplementary analysis to the previous evaluation of Luxturna, as Novartis has submitted new ...
Posted by Michael Wonder on 21 Apr 2021
Health economic assessment of Qarziba in patients with high-risk neuroblastoma
21 April 2021 - TLV has produced a health economic assessment for the regions for the drug Qarziba (dinutuximab beta). ...
Posted by Michael Wonder on 20 Apr 2021
Health economic assessment of Darzalex in multiple myeloma
19 April 2021 - TLV has produced a health economic assessment for the regions for the drug Darzalex in combination with ...